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respectively. Diarrhea (6.3%), fatigue (3.2%) and dyspnea (3.2%) were 
the most common grade 3/4 non-hematological toxicities. The most 
common drug-related toxicities (any grade) were pyrexia (11.6%), 
vomiting, nausea, diarrhea and asthenia (9.5%) and fatigue (8.4%). Tu-
mor Response Rate (CR/PR) in treated patients was 9.2%. The survival 
at 4.5 months (median follow-up) was 79% and the median PFS was 
3.1 months. Twenty patients (21.1%) died mainly because of disease 
progression.
Conclusion: Patients with locally advanced or metastatic NSCLC 
could beneﬁt from second-line pemetrexed, with a low incidence of 
hematological and non-hematological toxicities.
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The Ataxia Telangiectasia Mutated (ATM) gene is known to be a pro-
tein kinase that plays a central mediator of responses to DNA double-
strand breaks in cells. Therefore, ATM gene polymorphisms may act as 
important factors predicting the outcome of non-small cell lung cancer 
(NSCLC) patients treated with platinum combination. In order to evalu-
ate the role of ATM gene polymorphisms, seven genotypes of the ATM 
polymorphisms, IVS16-56G>A, IVS17+910G>A, IVS19-657G>A, 
IVS21-76C>T, IVS34-822C>T, IVS62+60A>G, IVS62-973A>C 
were determined in 300 Korean NSCLC patients who were staged as 
IIIA(n=48), IIIB (n=93) and IV (n=159). One-, three-, ﬁve-year sur-
vival was shown to be 57.6%, 11.7%, 4.7% respectively. Clinical stage, 
performance status, body weight loss (>5%) or response status to the 
treatment was correlated signiﬁcantly with survival (P=0.027, 0.038, 
0.076 <0.001 respectively). The frequencies for major and minor allele 
were as followings: 56% and 44% for IVS16-56G>A, 88% and 12% 
for IVS17+910G>A, 68% and 32% for IVS19-657G>A, 61% and 39% 
for IVS21-76C>T, 64% and 36% for IVS34-822C>T, 52% and 48% for 
IVS62+60A>G, 60% and 40% for IVS62-973A>C. When the effects of 
selected ATM genotypes were evaluated, any ATM genotype was not 
shown to have association with survival (log rank P=0.317 for IVS16-
56G>A, 0.451 for IVS17+910G>A, 0.520 for IVS19-657G>A, 0.542 
for IVS21-76C>T, 0.272 for IVS34-822C>T, 0.371 for IVS62+60A>G, 
0.470 for IVS62-973A>C). Therefore, our results suggest that poly-
morphisms of the ATM gene can not confer prognostic relevance in 
NSCLC patients treated with platinum combination. 
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Background: Because elderly pts may tolerate platinum-based combi-
nation chemotherapy poorly, single-agent chemotherapy is selected for 
the treatment regimen. However, retrospective subgroup analyses have 
consistently indicated that elderly pts indeed beneﬁt from platinum-
based combination chemotherapy as well as their younger counterparts. 
This phase II study evaluated the efﬁcacy and safety of carboplatin/
gemcitabine combination chemotherapy in elderly pts with advanced 
NSCLC.
Methods: Fifty-four pts aged more than 70 years old (median, 77; 
range, 70-88) with previously untreated advanced NSCLC were 
enrolled on this trial. Additional criteria included the presence of mea-
surable lesions, an Eastern Cooperative Oncology Group performance 
status of 0 or 1, and adequate organ function. Pts received carboplatin 
at an area under the curve of 4 mg/ml/min on the ﬁrst day and gem-
citabine at 1000 mg/m2 on the ﬁrst and eighth day of consecutive 3 
week periods. The primary endpoint was to determine the objective 
response rate of this platinum-doublet regimen. The RECIST criteria 
were used to measure response. 
Results: Enrolled pts included 15/39 with stage IIIB/IV diseases. Fifty-
one out of enrolled pts were eligible for efﬁcacy and safety analyses. 
The median number of treatment cycles was 4 (range, 1-7). Fifteen 
partial responses (response rate: 29%) were obtained. The median TTP 
was 3.9 months, and median overall survival was 15.9 months. Hema-
tological toxicities of grade 3/4 included leukopenia (46%), neutrope-
nia (72%) and thrombocytopenia (50%). Non-hematological toxicities 
of grade 3/4 included nausea (6%), appetite loss (7%), fatigue (7%) and 
infection (9%). 
Conclusion: The combination carboplatin-gemcitabine at these doses 
has shown activity with a favorable toxicity proﬁle for ﬁt elderly pts 
with advanced NSCLC.
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Background: Gemcitabine plus carboplatin (GC) therapy is active as 
ﬁrst-line treatment in advanced non-small-cell lung cancer (NSCLC). 
For nonprogressing patients, the timing of second-line chemotherapy 
for optimum clinical beneﬁt is uncertain. Docetaxel (D) is approved for 
second-line therapy in advanced NSCLC. This Phase III, randomized 
trial assessed the efﬁcacy and safety of D administered either immedi-
ately after initial GC therapy or upon disease progression (PD). 
Methods: Patients enrolled had either Stage IIIB with pleural effusion 
or Stage IV NSCLC. Prior chemotherapy for NSCLC was excluded. 
Gemcitabine 1000 mg/m2 was administered on Days 1, 8 followed by 
carboplatin AUC 5 on Day 1. After four 21-day cycles, nonprogres-
sors were randomized to either immediate D group (D 75 mg/m2 on 
Day 1 every 21 days, maximum of 6 cycles) or delayed D group (best 
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supportive care after randomization and same D regimen after ﬁrst evi-
dence of PD). Primary endpoint was overall survival (OS). Additional 
analyses included tumor response, toxicity, progression-free survival 
(PFS) and quality of life (QoL). 
Results: Table below summarizes results through May 6, 2007. Final 
data will be available in July. Enrollment totaled 564 patients; 393 pa-
tients received 4 cycles of GC therapy, and 308 patients were random-
ized equally to immediate D and delayed D groups. Patient demograph-
ics were well balanced between D arms. Initial GC therapy was well 
tolerated with major toxicities represented in myelosuppression, but 
only 7.7% of patients experienced G4 thrombocytopenia. D delivered 
immediately following GC therapy had a manageable toxicity proﬁle 
comparable to the delayed D arm. Post-randomization, a notable num-
ber of patients in the delayed D arm (N=60) never received D therapy, 
mainly due to PD or personal decision to discontinue. PFS in the im-
mediate D arm (6.0 months) was signiﬁcantly greater (p=<0.0001) than 
in the delayed D arm (2.8 months). OS trended in favor of immediate 
D therapy (11.9 months) by 2.5 months compared to delayed D therapy 
(9.4 months), but was not statistically signiﬁcant (p=0.1065). QoL 
average symptom burden index based on responses to a Lung Cancer 
Symptom Scale survey was not statistically different (p=0.43) compar-
ing the two D arms. 
Conclusions: NSCLC patients can be administered D immediately 
after ﬁrst-line GC therapy without a sacriﬁce in either toxicity or QoL. 
While the PFS analysis for each D group suggests a possible clinical 
beneﬁt for immediate D therapy, the OS result trended in favor of im-
mediate D therapy, but did not reach statistical signiﬁcance. 
Characteristic/Result Initial GC Delayed D Immediate D
N enrolled/randomized 564 155 153
 Mean age (range) 65 (36-87) 65 (36-85) 65 (41-87)
 Performance status 0,1:2, % 89:11 89:11 93:7
 Stage IIIB:IV, % 14:85 16:83 18:82
N assessed for safety 560 95 145
 G3-4 Neutropenia, % 31.8 33.7 33.1
 G3/G4 Thrombocytopenia, % 20.4/7.7 0/0 1.4/0
 G3-4 Febrile neutropenia, % 1.8 1.1 3.5
 G3-4 Anemia, % 13.0 0 0.7
 G3-4 Fatigue, % 5.9 3.2 9.6
 G3-4 Vomiting, % 2.3 1.1 0
 G3-4 Diarrhea, % 0.4 5.3 0.7
 G3-4 Neuropathy, % 0 0 0
 G3-4 Myalgia, % 0.2 1.1 0.7
 G3-4 Asthenia, % 2.1 1.1 2.1
N assessed for response 393 95 145
 Overall response rate (CR+PR), % 38.9 9.5 11.7
N assessed for survival - 155 153
 Median OS, months - 9.4 11.9
 12 Month survival rate, % - 41.2 48.3
 Patients censored for OS, n (%) - 25 (16.1%) 34 (22.2%)
 Median PFS, months - 2.8 6.0
 Patients censored for PFS, n (%) - 10 (6.4%) 9 (5.9%)
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Background: Previous data from our centre has shown that 50-60% 
of the patients require blood transfusion when treated with palliative 
chemotherapy. EPO has not been accepted for routine use in Denmark 
due to no shortage of blood for transfusions although the patients 
may have to accept low haemoglobin (Hb) values during treatment 
before transfusion. This may lead to reduced QOL and may lead to 
early stopping of treatment, and admissions which may be avoided 
with EPO. This study was initiated to study the use of EPO to prevent 
anaemia in not yet anaemic NSCLC patients undergoing chemotherapy. 
Investigated was not just the impact of EPO on the number of blood 
transfusions, but also the number of days admitted to hospital, cycles of 
chemotherapy and QOL.
Methods: In the EPO-group treatment with epoetin beta (NeoRecor-
mon®) 30.000 IE s.c. was initiated if Hb<13 g/dL, and stopped if 
Hb>14 g/dL. 52 chemotherapy-naïve patients with advanced NSCLC 
scheduled for 6 courses of Carboplatin (AUC5, d1) and Gemcitabine 
(1000 mg/m2) in PS=0-2 accepted inclusion in the study 3/2005 to 
1/2007. A matched control group of 52 patients selected from a cohort 
of 195 patients treated 2003-2005 with CaGem without EPO. Criteria 
for matching were gender, Hb (</≥), PS (0-1/2), WBC (</≥10), stage 
(III/IV), LDH (</≥UNL), and weight loss (</≥5%). 
Results: All together the study consisted of 104 patients, 52 in the 
EPO-group, and 52 in a matched control group: 38 patients fulﬁlled 
all 7 criteria for matching, 8 patients fulﬁlled 6 criteria, and 6 patients 
fulﬁlled 5 criteria. All pairs showed match with gender, Hb, and PS. 
One pair had no match for WBC, and 3 no match for stage, 7 for LDH 
and 11 for weight loss. The groups were very similar with regard to 
major criteria not matched for (Age 63.3 vs. 62.1 years, and BMI 24.0 
vs. 24.5). 
As of March 1st, 5 patients were still receiving CaGem in the EPO-
group. 25 in the EPO-group had initial Hb<13g/dL and started with 
EPO during the ﬁrst cycle of CaGem. Of the 27 patients presenting 
with Hb≥13g/dL, 21 patients received EPO after a median time of 26 
days. 
Survival of the EPO-group and controls were 7.6 and 7.4 months. 1 
year survival was 38% and 37%. Preliminary analyses showed the 
transfusions dropped 43% from 0.95 portion blood to 0.54 per given 
cycle CaGem (p=0.16) The number of cycles of CaGem per patient 
who had fulﬁlled chemotherapy March 1st was 4.4 cycles in the EPO 
group and 4.0 in the control group (0.20). Final analyses will be per-
formed July 31st. 
Conclusions: The matched pair design worked. Preliminary analyses 
showed a trend to less transfusions, and trend to being able to receive 
more chemotherapy when EPO was applied
